2,510 results match your criteria Carcinoid Gastrointestinal


High-grade well-differentiated neuroendocrine tumour of the cecum diagnosed following incisional hernia repair: a case report.

Acta Med Litu 2020 ;27(1):17-24

Centre of Abdominal Surgery, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

High-grade well-differentiated neuroendocrine tumour tumours (NETs) of gastrointestinal tract are rare; they can arise in any part of the digestive system and usually present in advanced stages. Low incidence and wide heterogeneity in the biological behaviour of such lesions pose a diagnostic and therapeutic challenge. Loco-regional NETs should be resected whenever feasible, potentially with a curative intent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6001/actamedica.v27i1.4262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305807PMC
January 2020

Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) s: A Single-Center Experience.

Balkan Med J 2020 Jun 23. Epub 2020 Jun 23.

Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms originating from the neuroendocrine system of the gastrointestinal tract and pancreas. There aren't many large well-designed studies investigating NETs in Turkey.

Aims: To define the clinicopathologic, demographic and survival features of patients with GEPNETs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/balkanmedj.galenos.2020.2020.1.126DOI Listing

Small Bowel Neoplasms: A Pictorial Review.

Radiographics 2020 Jul-Aug;40(4):1020-1038. Epub 2020 Jun 19.

From the Department of Radiology, Virginia Commonwealth University Health System, 1250 E Marshall St, Richmond, VA 23298.

Small bowel tumors are rare and account for approximately 3% of all gastrointestinal tumors in the United States. The incidence of small bowel neoplasms is rising-in particular, there is a rising incidence of small bowel carcinoid tumors. This may in part be due to small bowel lesion identification in an increasing number of cross-sectional imaging studies performed for other indications as well as increased use of advanced imaging techniques to assess specifically for small bowel disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2020200011DOI Listing

Carcinoid Tumors of the Orbit and Ocular Adnexa.

Ophthalmic Plast Reconstr Surg 2020 Jun 2. Epub 2020 Jun 2.

Division of Orbital and Ophthalmic Plastic Surgery and*Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, New York.

Purpose: Well-differentiated neuroendocrine or carcinoid tumors are found most commonly in the gastrointestinal tract. When metastatic to the orbit, they tend to have a propensity for the extraocular muscles. The purpose of this study was to better understand the diversity in presentation of orbital carcinoid disease and to determine predictors for survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001715DOI Listing

Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence.

Lung Cancer 2020 Jul 5;145:85-94. Epub 2020 May 5.

Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan; Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.

Introduction: The majority of pulmonary carcinoid (PC) tumors can be cured by surgical resection alone, but a significant proportion of patients experience recurrence. As PC is insensitive to conventional chemotherapy, further clarification of the molecular mechanisms of metastasis is needed in order to develop targeted therapeutics.

Methods: We performed comprehensive whole-exome sequencing (WES) of primary tumors and corresponding normal lung tissues from 14 PC patients (including 4 patients who developed postsurgical distant metastasis) and RNA sequencing of primary tumors from 6 PC patients (including 4 patients who developed postsurgical distant metastasis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.03.027DOI Listing

Neuroendocrine Tumors of the Pancreatobiliary and Gastrointestinal Tracts.

Surg Clin North Am 2020 Jun 1;100(3):635-648. Epub 2020 Apr 1.

Section of General, Vascular, and Thoracic Surgery, Virginia Mason Medical Center, 1100 Ninth Avenue, CS-G6, Seattle, WA 98101, USA; University of Washington, Seattle, WA, USA. Electronic address:

Incidence of neuroendocrine tumors (NETs) is increasing, including those of the gastroenteropancreatic tract. A proper understanding of the management of this disease has become necessary for the general surgeon. This article addresses current guidelines for diagnosis and localization of NETs, including somatostatin receptor PET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suc.2020.02.010DOI Listing

Hereditary Syndromes in Neuroendocrine Tumors.

Authors:
Mark A Lewis

Curr Treat Options Oncol 2020 Apr 30;21(6):50. Epub 2020 Apr 30.

Gastrointestinal Oncology, Intermountain Healthcare, 5171 S. Cottonwood Street, Bldg. 1. Ste. 610, Murray, UT, 84107, USA.

Opinion Statement: Oncologists should be able to discern the salient clinical features of the most common germline mutations that give rise to neuroendocrine tumors. Astute recognition of an index patient affected by a hereditary syndrome can lead to a "tip-of-the-iceberg" phenomenon whereby their entire kindred can then be proactively monitored and managed potentially with substantial reduction of morbidity and mortality. Through careful history-taking, as well as thoughtful assimilation of findings from the physical exam, biochemical laboratories, scans, and pathology reports, the clinician can spot phenotypic clues that distinguish these familial patterns from sporadic cases of tumorigenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-020-00749-5DOI Listing

Evaluation of Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors.

World J Gastroenterol 2020 Apr;26(13):1513-1524

Department of Nuclear Medicine, Santiago de Compostela´s University Hospital, Santiago de Compostela 15706, A Coruña, Spain.

Background: Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors.

Aim: To determine the impact of PRRT on quality of life, radiologic and metabolic response, overall survival, prognostic factors and toxicity.

Methods: Thirty-six patients treated with Lu-PRRT from 2016 to 2019 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v26.i13.1513DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152518PMC

A primary neuroendocrine tumor of the left ventricle presenting with diarrhea-an unusual experience and literature review.

Diagn Pathol 2020 Apr 3;15(1):32. Epub 2020 Apr 3.

Department of Pathology, The Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou, China.

Background: Neuroendocrine tumors (NETs) can secrete bioactive amines in the bloodstream, resulting in the carcinoid syndrome characterized by diarrhea and flushing. The frequency of occurrence of primary cardiac neuroendocrine neoplasms is lesser than that of metastases, and hence, metastases must be adequately ruled out before diagnosis. Cardiac tumors, both primary and metastatic, mainly result in heart-related symptoms, such as heart failure and acquired valvular dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-020-00935-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119177PMC

Peptide Receptor Radionuclide Therapy: An Emerging Treatment for Gastrointestinal Neuroendocrine Tumors.

Clin J Oncol Nurs 2020 Apr;24(2):129-133

University of Kentucky.

Neuroendocrine tumors (NETs) are comprised of biologically diverse neoplasms. The presence of systemic symptoms is dependent on NET location and differentiation. New treatment modalities have become available, offering patients improved symptom management and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/20.CJON.129-133DOI Listing

[Two Cases of Goblet Cell Carcinoid of Appendix Treated with Oxaliplatin-Based Adjuvant Chemotherapy].

Gan To Kagaku Ryoho 2019 Dec;46(13):2413-2415

Dept. of Gastrointestinal and Pediatric Surgery, Tokyo Medical University.

Although there are reports of goblet cell carcinoid(GCC)treated by chemotherapy using the treatment protocol for colon cancer, the benefit of chemotherapy for GCC remains controversial and unclear. Herein we report 2 cases of patients with GCC who were successfully treated by surgical resection and oxaliplatin-based adjuvant chemotherapy, without evidence of recurrence. The first case was a 57-year-old man who underwent laparoscopic ileocecal resection after being diagnosed with adenocarcinoma of the appendix by biopsy via colonoscopy. Read More

View Article

Download full-text PDF

Source
December 2019

Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study.

Pancreas 2020 03;49(3):408-412

Medical Affairs, Lexicon Pharmaceuticals, Inc, The Woodlands, TX.

Objectives: We evaluated carcinoid syndrome (CS) symptoms and the real-world effectiveness of telotristat ethyl (TE) among patients with ≤3 bowel movements (BM) per day.

Methods: Patients with CS initiating TE between March and November 2017 could participate in a nurse support program collecting demographic and CS symptom data before TE initiation (baseline) and during ≥1 monthly follow-up within 3 months. Symptoms for patients averaging ≤3 BM/d at baseline were evaluated using pre/post-Student t tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001496DOI Listing

Somatostatin Analogs in Clinical Practice: a Review.

Int J Mol Sci 2020 Feb 29;21(5). Epub 2020 Feb 29.

Department of Endocrinology, "La Paz" University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain.

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors. They should also be considered an effective and safe therapeutic alternative to corticotropinomas, gonadotropinomas, and prolactinomas resistant to dopamine agonists. Somatostatin analogs have also shown to be useful in the treatment of other endocrine diseases (congenital hyperinsulinism, Graves' orbitopathy, diabetic retinopathy, diabetic macular edema), non-endocrine tumors (breast, colon, prostate, lung, and hepatocellular), and digestive diseases (chronic refractory diarrhea, hepatorenal polycystosis, gastrointestinal hemorrhage, dumping syndrome, and intestinal fistula). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21051682DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084228PMC
February 2020

Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms.

Horm Metab Res 2020 Feb 27. Epub 2020 Feb 27.

1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Neuroendocrine neoplasms (NENs) are rare tumours that arise mainly in the gastrointestinal or pulmonary system. Most NENs are well-differentiated and may obtain prolonged survival besides the presence of metastatic disease; however, a subset (poorly differentiated NENs) may display a truly aggressive behaviour exhibiting a poor prognosis. The recently developed classification systems along with advances in functional imaging have helped stratify patients to the administration of appropriate therapeutic options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1110-7251DOI Listing
February 2020

Incidence of Atrioventricular Block After Valve Replacement in Carcinoid Heart Disease.

Cardiol Res 2020 Feb 26;11(1):56-60. Epub 2020 Jan 26.

Division of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL 33606, USA.

Background: Carcinoid heart disease (CaHD) is a rare condition that has a high impact on the morbidity and mortality of its patients. Once heart failure symptoms develop in the patient with CaHD, cardiac valve surgery is often the only effective treatment. Although atrioventricular block (AVB) is a known postoperative complication of the valve surgery, the incidence of AVB in this population has not been well described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/cr986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011921PMC
February 2020

Robotic-assisted complete mesocolic excision, central vascular ligation and para-aortic lymph node dissection in multifocal carcinoid: A case report and technical description.

Int J Surg Case Rep 2020 11;67:262-266. Epub 2020 Feb 11.

Gastrointestinal Clinical Institute, Epworth Healthcare, Victoria, Australia; Department of Cancer Surgery, Peter MacCallum Cancer Centre, Victoria, Australia; Department of Surgery, Alfred Health, Victoria, Australia. Electronic address:

Introduction: Neuroendocrine tumours are the most common type of primary small bowel neoplasm. Consensus guidelines recommend a multimodal approach to treatment of such tumours, with aggressive surgical resection remaining the mainstay of management. There is evidence that complete mesocolic excision (CME) of lymph nodes is associated with superior oncological outcomes including longer disease-free survival in patients with colorectal cancer than standard lymph node dissection and there is increasing evidence to suggest that the robotic approach may be superior to laparoscopic or open CME. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2020.02.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036704PMC
February 2020

Carcinoid Tumor: Advances in Treatment Options.

Cureus 2020 Jan 13;12(1):e6641. Epub 2020 Jan 13.

Gastroenterology, AdventHealth, Orlando, USA.

Small bowel neoplasms are rare, accounting for only 3%-6% of all gastrointestinal neoplasms. Carcinoid tumors represent a large portion of these (20%-30%), making them the second most common small bowel malignancy after adenocarcinoma. Gastrointestinal carcinoids constitute 70% of all neuroendocrine tumors, and out of those, 42% originate in the small bowel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.6641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011579PMC
January 2020

Multiple liver metastases originating from synchronous double cancer of neuroendocrine tumor and rectal cancer: a case report.

Surg Case Rep 2020 Feb 13;6(1):36. Epub 2020 Feb 13.

The Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan.

Background: Neuroendocrine tumor (NET) is a relatively rare tumor and can develop in almost any organ, but primary mesenteric NETs are extremely rare. In addition, liver metastases from synchronous double cancer of neuroendocrine tumor graded as G1 and second primary malignancies (SPMs) have never been reported before. We herein report a case of multiple liver metastases from synchronous double cancer of NET (G1) at the ileal mesentery and rectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-020-0800-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018860PMC
February 2020

Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?

Authors:
Denis M McCarthy

Int J Mol Sci 2020 Jan 19;21(2). Epub 2020 Jan 19.

Departments of Medicine & Biochemistry, Division of Gastroenterology and Hepatology, University of New Mexico School of Medicine and Raymond G. Murphy Veterans Administration Medical Center, 1501 San Pedro Blvd. SE, Albuquerque, NM 87108, USA.

Neuroendocrine tumors (NETs) throughout the body are the focus of much current interest. Most occur in the gastrointestinal tract and have shown a major increase in incidence over the past 30 years, roughly paralleling the world-wide increase in the use of proton pump inhibitor (PPI) drugs. The greatest rise has occurred in gastric carcinoids (g-NETs) arising from enterochromaffin-like (ECL) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21020662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014182PMC
January 2020

Cardiac Magnetic Resonance for Diagnosis of Neuroendocrine Tumor Metastases to the Right and Left Ventricles with Carcinoid Heart Disease.

Case Rep Cardiol 2019 5;2019:8746413. Epub 2019 Dec 5.

Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa FL, USA.

A 76-year-old male with a small bowel neuroendocrine tumor with hepatic metastases presented with new onset lower extremity swelling, bloating, and weight gain which ultimately lead to cardiac magnetic resonance (CMR) to evaluate for cardiac involvement of disease. CMR showed right and left ventricular myocardial metastases along with findings suggestive of carcinoid heart disease. The patient had severe tricuspid valve regurgitation necessitating surgical valve repair. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8746413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915124PMC
December 2019

Direct costs of carcinoid syndrome diarrhea among adults in the United States.

World J Gastroenterol 2019 Dec;25(47):6857-6865

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

Background: The burden of carcinoid syndrome (CS) among patients with neuroendocrine tumors is substantial and has been shown to result in increased healthcare resource use and costs. The incremental burden of CS diarrhea (CSD) is less well understood, particularly among working age adults who make up a large proportion of the population of patients with CS.

Aim: To estimate the direct medical costs of CSD to a self-insured employer in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i47.6857DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931008PMC
December 2019

Gastrointestinal: An unusual cause of lower gastrointestinal bleed: Ileal carcinoid tumor.

J Gastroenterol Hepatol 2020 Mar 1;35(3):359. Epub 2019 Dec 1.

Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14883DOI Listing

Treatment of atypical pulmonary carcinoid with combination ipilimumab and nivolumab.

BMJ Case Rep 2019 Nov 28;12(11). Epub 2019 Nov 28.

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.

Atypical pulmonary carcinoid (APC) is a lung neuroendocrine neoplasm (NEN), whose treatment draws from management of gastrointestinal NENs and small-cell lung carcinoma. We present a patient with recurrent metastatic APC and persistent mediastinal lymphadenopathy refractory to cisplatin and etoposide. After pursuing alternative treatments, he returned with significant progression, including diffuse subcutaneous nodules, weight loss and worsening cough. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-231029DOI Listing
November 2019

Oesophageal carcinoma mimicking a submucosal lesion: A case report.

World J Gastrointest Endosc 2019 Nov;11(11):541-547

Department of Medical Gastroenterology, Government Stanley Medical College, Chennai 600001, Tamil Nadu, India.

Background: Oesophageal cancer is the fourth most common cause of cancer-related deaths in India. Esophageal squamous cell carcinomas (ESCCs) arise from the epithelial layer, and commonly present as polypoidal, ulcerative or ulceroproliferative growth in the oesophageal lumen. In contrast, oesophageal submucosal tumours are a distinct group of tumours arising from the mesenchyme (examples include leiomyoma, fibrovasculoma, lipoma, granular cell tumour or carcinoid), and mostly do not breach the mucosa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4253/wjge.v11.i11.541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875686PMC
November 2019

Multidisciplinary team management of carcinoid heart disease.

Endocr Connect 2019 Dec;8(12):R184-R199

Birmingham Neuroendocrine Tumour Centre, University Hospitals Birmingham (Queen Elizabeth), NHS Hospitals Foundation Trust, Birmingham, UK.

Carcinoid heart disease (CHD) is a consequence of valvular fibrosis triggered by vasoactive substances released from neuroendocrine tumours, classically in those with metastatic disease and resulting in tricuspid and pulmonary valve failure. CHD affects one in five patients who have carcinoid syndrome (CS). Valve leaflets become thickened, retracted and immobile, resulting most often in regurgitation that causes right ventricular dilatation and ultimately, right heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-19-0413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933832PMC
December 2019

Impact of Referral Center Pathology Review on Diagnosis and Management of Patients With Appendiceal Neoplasms.

Arch Pathol Lab Med 2020 Jun 12;144(6):764-768. Epub 2019 Nov 12.

From the Department of Pathology, University of Utah, Salt Lake City (Dr Jedrzkiewicz); the Department of Pathology, Yokohama City University, Yokohama, Japan (Dr Tateishi); and the Departments of Pathology (Drs Kirsch, Conner, Riddell, and Pollett) and Surgery (Drs Bischof, McCart, and Govindarajan, and Ms Taylor), Sinai Health System, University of Toronto, Toronto, Ontario, Canada.

Context.—: Data regarding the clinical impact of subspecialist pathology review of appendiceal neoplasms are limited.

Objective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2019-0214-OADOI Listing

Management of Gastrointestinal Neuroendocrine Tumors.

Clin Med Insights Endocrinol Diabetes 2019 24;12:1179551419884058. Epub 2019 Oct 24.

Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, USA.

Neuroendocrine neoplasms (NENs) are derived from neuroendocrine cell system and can have benign or malignant characteristics. They are rare tumors, but have been increasing in incidence over the past 40 years. Patients with NENs may develop symptoms due to primary tumor invasion, metastasis, or from secretion of hormonally active tumor substances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179551419884058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820165PMC
October 2019
1 Read

Rare Orbital Metastasis Originating From a Neuroendocrine Tumor.

Radiol Technol 2019 Nov;91(2):112-119

Background: This case study details a rare orbital metastasis originating from the gastrointestinal tract. A patient presented with proptosis of the right eye precipitated by a slow-growing orbital tumor. A biopsy confirmed a low-grade neuroendocrine tumor. Read More

View Article

Download full-text PDF

Source
November 2019

Treatment of Gastroenteropancreatic Neuroendocrine Tumors.

Surg Pathol Clin 2019 Dec;12(4):1045-1053

Program in Carcinoid and Neuroendocrine Tumors, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

Neuroendocrine tumors (NETs) represent a group of biologically and clinically heterogeneous neoplasms arising from the diffuse neuroendocrine system. Although NETs may develop in almost any organ, they commonly arise in the gastrointestinal tract and pancreas and are referred to as gastroenteropancreatic (GEP)-NETs when they arise from these sites. In recent years, advances in understanding of the biology of NETs have resulted in an expansion in treatment options and improved survival for patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2019.08.011DOI Listing
December 2019
1 Read

Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.

J Patient Rep Outcomes 2019 Oct 26;3(1):64. Epub 2019 Oct 26.

Lexicon Pharmaceuticals Inc., 8800 Technology Forest Pl, The Woodlands, TX, USA.

Background: Carcinoid syndrome is associated with a reduced quality of life that can be attributed to symptoms such as diarrhea and fatigue as well as social and financial issues. This study was conducted to psychometrically assess meaningful change in bowel movement frequency among carcinoid syndrome patients using data from the TELESTAR clinical study.

Methods: An anchor-based approach for deriving meaningful change thresholds consisted of mapping change from baseline bowel movement frequency to other patient-reported assessments of change. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41687-019-0153-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815313PMC
October 2019

Inhibition of serotonin synthesis: A novel therapeutic paradigm.

Authors:
Michael Bader

Pharmacol Ther 2020 01 17;205:107423. Epub 2019 Oct 17.

Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany; University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany; Charité University Medicine, Charitéplatz 1, 10117 Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site, Berlin, Germany. Electronic address:

The rate-limiting enzyme in serotonin synthesis is tryptophan hydroxylase (TPH). There are two independent serotonin systems in the body characterized by two isoforms of TPH, TPH1 and TPH2. While TPH2 synthesizes serotonin in the brain, TPH1 is expressed in the gut and in other peripheral tissues and supplies platelets in the circulation with serotonin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2019.107423DOI Listing
January 2020
2 Reads

La néoplasie endocrinienne multiple de type 1 : mise au point après le congrès de l’ENETS 2019: Multiple Endocrine Neoplasia Type 1: Development after the ENETS 2019 Congress.

Ann Endocrinol (Paris) 2019 Sep;80 Suppl 1:S19-S28

Service endocrinologie et maladies métaboliques, pôle cardio-vasculaire et métabolique, CHU Larrey-Rangueil, Toulouse, France.

Multiple Endocrine Neoplasia Type 1 (NEM1) is related to mutations of the menin gene. It is an autosomal dominant disease. Its prevalence is about 1/30 000 with a hugh penetrance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(19)30113-1DOI Listing
September 2019
1 Read

SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.

Histopathology 2020 Mar 24;76(4):550-559. Epub 2020 Jan 24.

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.

Aims: Neuroendocrine neoplasms (NNs) range from well to poorly differentiated and indolent to highly aggressive. The site of origin in metastatic NNs has therapeutic and prognostic implications. SATB2 is a transcriptional regulator involved in osteoblastic and neuronal differentiation and is a sensitive and specific marker of colorectal epithelium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14012DOI Listing
March 2020
3 Reads

Treatment patterns and outcomes in goblet cell carcinoid tumors of the appendix.

J Surg Oncol 2019 Dec 8;120(7):1096-1101. Epub 2019 Oct 8.

Division of Colorectal Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Background: Goblet cell carcinoid (GCC) tumors of the appendix are a rare malignancy. We aim to examine the overall survival per stage and the relationship between different treatment modalities and outcomes for patients with GCC tumors of the appendix.

Methods: We identified patients with GCC tumors of the appendix from the National Cancer Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25723DOI Listing
December 2019
1 Read

Lymphovascular invasion as a prognostic value in small rectal neuroendocrine tumor treated by local excision: A systematic review and meta-analysis.

Pathol Res Pract 2019 Nov 21;215(11):152642. Epub 2019 Sep 21.

Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Republic of Korea.

Because rectal neuroendocrine tumors (NETs) are usually small-sized despite of malignant potential, endoscopic resection techniques are recommended. It is unclear whether the lymphovascular invasion (LVI) in the endoscopic resected specimens of small rectal NETs should be indicated for completion surgery. We performed a systematic review and meta-analysis for the incidence of LVI in small rectal NETs (≤20 mm) treated by endoscopic resection and its prognostic impacts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.152642DOI Listing
November 2019

Primary neuroendocrine tumour of the left ventricle.

Eur J Cardiothorac Surg 2020 Apr;57(4):806-808

Division of Cardiothoracic Surgery, Department of Surgery, University of South Florida College of Medicine, Tampa, FL, USA.

Neuroendocrine tumours are rare neoplasms typically arising in the gastrointestinal tract that may result in carcinoid syndrome and/or acquired valvular dysfunction. Herein, we present a unique case of a 68-year-old asymptomatic woman with a primary left ventricular neuroendocrine tumour. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejcts/ezz265DOI Listing
April 2020
2 Reads

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

PLoS One 2019 17;14(9):e0221994. Epub 2019 Sep 17.

Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.

Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET).Enrolled patients had metastatic, well-differentiated NET of non-pancreatic gastrointestinal or unknown origin, with/without carcinoid symptoms, had failed ≥1 systemic chemotherapy, and were taking a somatostatin analog (SSA). Oral once-daily CC-223 was administered in 28-day cycles starting at 45 mg (n = 24), with a subsequent cohort starting at 30 mg (n = 23). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221994PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748410PMC
March 2020
1 Read

68Ga-DOTATATE PET/CT of Ectopic Cushing Syndrome Due to Appendicular Carcinoid.

Clin Nucl Med 2019 Nov;44(11):881-882

From the Department of Endocrinology, Seth GS Medical College, Parel, Mumbai, India.

Approximately 5% to 15% cases of endogenous Cushing syndrome are due to ectopic adrenocorticotrophic hormone (ACTH)-producing neuroendocrine tumors, which are commonly located in bronchopulmonary system, thymus, and gastrointestinal tract including pancreas. Although carcinoid tumors of the appendix are revealed in 0.3% of patients undergoing routine appendectomy, ACTH-secreting appendicular carcinoid is a rare entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002766DOI Listing
November 2019
2 Reads

Finding carcinoid tumor before bariatric surgery. Is preoperative endoscopy necessary? Case report.

Int J Surg Case Rep 2019 20;62:132-134. Epub 2019 Aug 20.

Türkçapar Bariatrics, Obesity Center, Istanbul, Turkey; Acibadem Fulya Hospital, Istanbul, Turkey.

Introduction: Carcinoid tumors are endocrine system-related lesions and 4% of the gastrointestinal tract's neuroendocrine tumors (NET) originate from stomach. In recent years, gastric carcinoid tumors have been reported at increasing rates on endoscopies. In this article, we will present a case of gastric carcinoid tumor detected at the upper gastrointestinal (GI) endoscopy during preoperative bariatric surgery workup. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2019.08.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734182PMC
August 2019
1 Read

Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea.

Expert Rev Pharmacoecon Outcomes Res 2019 Aug 26:1-5. Epub 2019 Aug 26.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

: We estimated the indirect costs of work productivity burden from carcinoid syndrome diarrhea (CSD) among employed, insured adults in the United States. : Retrospective cohort study of patients ≥18 years old with CS who did and did not have CSD (2014-2016). Eligible patients had continuous health plan enrollment for ≥12 months prior to their first CS claim and for ≥30 days after. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2019.1660646DOI Listing
August 2019
1 Read

Management of Diarrhea in Patients With Carcinoid Syndrome.

Pancreas 2019 09;48(8):961-972

Division of Medical Oncology, Mayo Clinic, Rochester, MN.

Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring in the gastrointestinal tract. The global incidence of NETs has increased in the past 15 years, likely due to better diagnostic methods. Small-bowel NETs are frequently associated with carcinoid syndrome (CS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867674PMC
September 2019
1 Read
2.959 Impact Factor

A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms.

Neuroendocrinology 2020 30;110(5):377-383. Epub 2019 Jul 30.

Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA,

Background: Ibrutinib is an orally administered inhibitor of Bruton's tyrosine kinase (Btk). Preclinical data suggest that mast cells are recruited within neuroendocrine neoplasms (NENs) where they stimulate angiogenesis and tumor growth. Ibrutinib inhibits mast cell degranulation and has been associated with regression of tumors in a mouse insulinoma model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502383DOI Listing
July 2019
3 Reads

Mesenteric Tuberculosis Masquerading as Carcinoid Tumor on Conventional Imaging and DOTANOC Positron Emission Tomography/Computed Tomography: Uncommon Presentation of a Common Disease.

Indian J Nucl Med 2019 Jul-Sep;34(3):216-219

Department of Radio-Diagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.

Carcinoid tumor of the mesentery has a classical imaging morphology. A specific diagnosis can often be provided on the basis of clinical history, elevated serum neuroendocrine markers, and uptake on somatostatin receptor-based radiotracer studies. Although a number of inflammatory and neoplastic conditions may mimic carcinoid tumor on many of these modalities, uptake on Ga-DOTANOC positron emission tomography/computed tomography (PET/CT) is considered specific. Read More

View Article

Download full-text PDF

Source
http://www.ijnm.in/text.asp?2019/34/3/216/260750
Publisher Site
http://dx.doi.org/10.4103/ijnm.IJNM_29_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593933PMC
July 2019
5 Reads

A case of feline primary duodenal carcinoid with intestinal hemorrhage.

J Vet Med Sci 2019 Aug 28;81(8):1086-1089. Epub 2019 Jun 28.

Laboratory of Veterinary Surgery, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan.

A 15-year-old neutered male Persian cat was presented with recurrent hematemesis and melena. Abdominal ultrasonography and computed tomography revealed a mass in the proximal descending duodenal wall. Endoscopic examination revealed hemorrhage on the luminal side of the mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1292/jvms.19-0110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715922PMC
August 2019
4 Reads

Multimodality imaging in carcinoid heart disease.

Open Heart 2019 4;6(1):e001060. Epub 2019 Jun 4.

Department of Cardiology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Neuroendocrine neoplasms arise from the gastrointestinal tract and can lead to carcinoid syndrome. Carcinoid heart disease affects more than half of these patients and is the initial presentation of carcinoid syndrome in up to 20 % of patients. Carcinoid heart disease typically leads to valve dysfunction, but in rare instances, carcinoid tumours can also metastasise to the endocardium and myocardium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/openhrt-2019-001060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560671PMC
June 2019
11 Reads